RxDoctor Payments Data

Priyanka Patel

Gastroenterology · Orange City, FLNPI 1346029550

Payments from drug & device makers

$3,300in general payments, 2019–2025

Across 104 payments — averaging $31.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$750
  • Johnson & Johnson$633
  • Madrigal Pharmaceuticals$322
  • Celltrion USA Inc.$291
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$233
  • Phathom Pharmaceuticals, Inc.$197
  • plus $874 from 11 others

What the payments were for

  • Food & beverage$3,13195%
  • Education$1695%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,300 in reported general payments places this provider in the 45th percentile of 1,388 gastroenterology providers in Florida.

See all gastroenterology providers in Florida

Medicare billing

Part B allowed, 2024
$47,114
Medicare patients
257
Services billed
579

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide27$30,698
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates94$5,805
Pantoprazole Sodium141$1,877
ClenpiqSod Picosulf/Mag Ox/Citric Ac11$1,855
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl109$1,790
Omeprazole85$1,644
Colestipol Hcl16$1,047
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl44$745
Dicyclomine Hcl29$533
Ondansetron OdtOndansetron14$481
Famotidine35$415
Sucralfate11$331
Hydrocortisone14$101

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$750$30,69827 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,388 gastroenterology providers in Florida.

Other gastroenterology in Orange City

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →